A 59-year-old kidney recipient was diagnosed with a late onset of severe chronic inflammatory demyelinating polyradiculoneuropathy and almost fully recovered after stopping tacrolimus and one course of intravenous immunoglobulin treatment. Unique features of this patient are the unusually long time lapse between initiation of tacrolimus and the adverse effect (10 years), a strong causality link and several arguments pointing toward an inflammatory etiology. When facing new neurological signs and symptoms in graft recipients, it is important to bear in mind the possibility of a drug-induced adverse event. Discontinuation of the suspect drug and immu-nomodulation are useful treatment options
Tacrolimus is an immunosuppressive agent that inhibitscytokine synthesis and blocks T-cell developme...
none7A 55-year-old Caucasian man who had received a second kidney graft in July 1993, was switched f...
Intrduction. Tacrolimus (fujimycin or FK506) is a potent immunosuppressive drug with growing usag...
A 59-year-old kidney recipient was diagnosed with a late onset of severe chronic inflammatory demyel...
Patients, in particular recipients of orthotopic liver transplants, receiving the immunosuppressant ...
Abstract Background Tacrolimus and cyclosporine, both calcineurin inhibitors, can cause neurological...
Tacrolimus is currently the most commonly prescribed immunosuppressant. Tacrolimus allowed intestina...
Tacrolimus is an immunosuppressive agent that can show a wide variety of neurological side effects, ...
INTRODUCTION: Tacrolimus is routinely used to prevent rejection after organs’ transplantation. Neuro...
Tacrolimus has become an important cornerstone in the prevention of rejection after kidney transplan...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Copyright © 2013 Giuseppe Bersani et al. This is an open access article distributed under the Creati...
Several neurological side effects induced by tacrolimus are described in the scientific literature, ...
Summary: Tacrolimus is an immunosuppressive agent that can show a wide variety of neurologic side ef...
Tacrolimus is a widely used macrolide immunosuppressant in transplant surgery, with mild and major n...
Tacrolimus is an immunosuppressive agent that inhibitscytokine synthesis and blocks T-cell developme...
none7A 55-year-old Caucasian man who had received a second kidney graft in July 1993, was switched f...
Intrduction. Tacrolimus (fujimycin or FK506) is a potent immunosuppressive drug with growing usag...
A 59-year-old kidney recipient was diagnosed with a late onset of severe chronic inflammatory demyel...
Patients, in particular recipients of orthotopic liver transplants, receiving the immunosuppressant ...
Abstract Background Tacrolimus and cyclosporine, both calcineurin inhibitors, can cause neurological...
Tacrolimus is currently the most commonly prescribed immunosuppressant. Tacrolimus allowed intestina...
Tacrolimus is an immunosuppressive agent that can show a wide variety of neurological side effects, ...
INTRODUCTION: Tacrolimus is routinely used to prevent rejection after organs’ transplantation. Neuro...
Tacrolimus has become an important cornerstone in the prevention of rejection after kidney transplan...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Copyright © 2013 Giuseppe Bersani et al. This is an open access article distributed under the Creati...
Several neurological side effects induced by tacrolimus are described in the scientific literature, ...
Summary: Tacrolimus is an immunosuppressive agent that can show a wide variety of neurologic side ef...
Tacrolimus is a widely used macrolide immunosuppressant in transplant surgery, with mild and major n...
Tacrolimus is an immunosuppressive agent that inhibitscytokine synthesis and blocks T-cell developme...
none7A 55-year-old Caucasian man who had received a second kidney graft in July 1993, was switched f...
Intrduction. Tacrolimus (fujimycin or FK506) is a potent immunosuppressive drug with growing usag...